345 related articles for article (PubMed ID: 35883484)
1. Emerging Link between Tsc1 and FNIP Co-Chaperones of Hsp90 and Cancer.
Backe SJ; Sager RA; Meluni KA; Woodford MR; Bourboulia D; Mollapour M
Biomolecules; 2022 Jul; 12(7):. PubMed ID: 35883484
[TBL] [Abstract][Full Text] [Related]
2. Tumor suppressor Tsc1 is a new Hsp90 co-chaperone that facilitates folding of kinase and non-kinase clients.
Woodford MR; Sager RA; Marris E; Dunn DM; Blanden AR; Murphy RL; Rensing N; Shapiro O; Panaretou B; Prodromou C; Loh SN; Gutmann DH; Bourboulia D; Bratslavsky G; Wong M; Mollapour M
EMBO J; 2017 Dec; 36(24):3650-3665. PubMed ID: 29127155
[TBL] [Abstract][Full Text] [Related]
3. The FNIP co-chaperones decelerate the Hsp90 chaperone cycle and enhance drug binding.
Woodford MR; Dunn DM; Blanden AR; Capriotti D; Loiselle D; Prodromou C; Panaretou B; Hughes PF; Smith A; Ackerman W; Haystead TA; Loh SN; Bourboulia D; Schmidt LS; Marston Linehan W; Bratslavsky G; Mollapour M
Nat Commun; 2016 Jun; 7():12037. PubMed ID: 27353360
[TBL] [Abstract][Full Text] [Related]
4. A specialized Hsp90 co-chaperone network regulates steroid hormone receptor response to ligand.
Backe SJ; Sager RA; Regan BR; Sit J; Major LA; Bratslavsky G; Woodford MR; Bourboulia D; Mollapour M
Cell Rep; 2022 Jul; 40(2):111039. PubMed ID: 35830801
[TBL] [Abstract][Full Text] [Related]
5. The Role of Heat Shock Protein-90 in the Pathogenesis of Birt-Hogg-Dubé and Tuberous Sclerosis Complex Syndromes.
Woodford MR; Backe SJ; Sager RA; Bourboulia D; Bratslavsky G; Mollapour M
Urol Oncol; 2021 Jun; 39(6):322-326. PubMed ID: 32327294
[TBL] [Abstract][Full Text] [Related]
6. Sporadic renal angiomyolipoma in a patient with Birt-Hogg-Dubé: chaperones in pathogenesis.
Sager RA; Woodford MR; Shapiro O; Mollapour M; Bratslavsky G
Oncotarget; 2018 Apr; 9(31):22220-22229. PubMed ID: 29774133
[TBL] [Abstract][Full Text] [Related]
7. The mTOR Independent Function of Tsc1 and FNIPs.
Sager RA; Woodford MR; Mollapour M
Trends Biochem Sci; 2018 Dec; 43(12):935-937. PubMed ID: 30361061
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of Hsp90 and mTOR inhibitors as potential drugs for the treatment of TSC1/TSC2 deficient cancer.
Mrozek EM; Bajaj V; Guo Y; Malinowska IA; Zhang J; Kwiatkowski DJ
PLoS One; 2021; 16(4):e0248380. PubMed ID: 33891611
[TBL] [Abstract][Full Text] [Related]
9. TSC2 missense mutations inhibit tuberin phosphorylation and prevent formation of the tuberin-hamartin complex.
Nellist M; Verhaaf B; Goedbloed MA; Reuser AJ; van den Ouweland AM; Halley DJ
Hum Mol Genet; 2001 Dec; 10(25):2889-98. PubMed ID: 11741832
[TBL] [Abstract][Full Text] [Related]
10. Pathological mutations in TSC1 and TSC2 disrupt the interaction between hamartin and tuberin.
Hodges AK; Li S; Maynard J; Parry L; Braverman R; Cheadle JP; DeClue JE; Sampson JR
Hum Mol Genet; 2001 Dec; 10(25):2899-905. PubMed ID: 11741833
[TBL] [Abstract][Full Text] [Related]
11. Mutation of the co-chaperone Tsc1 in bladder cancer diminishes Hsp90 acetylation and reduces drug sensitivity and selectivity.
Woodford MR; Hughes M; Sager RA; Backe SJ; Baker-Williams AJ; Bratslavsky MS; Jacob JM; Shapiro O; Wong M; Bratslavsky G; Bourboulia D; Mollapour M
Oncotarget; 2019 Oct; 10(56):5824-5834. PubMed ID: 31645902
[TBL] [Abstract][Full Text] [Related]
12. Tuberin and hamartin are aberrantly expressed and linked to clinical outcome in human breast cancer: the role of promoter methylation of TSC genes.
Jiang WG; Sampson J; Martin TA; Lee-Jones L; Watkins G; Douglas-Jones A; Mokbel K; Mansel RE
Eur J Cancer; 2005 Jul; 41(11):1628-36. PubMed ID: 15951164
[TBL] [Abstract][Full Text] [Related]
13. Tsc2 gene inactivation causes a more severe epilepsy phenotype than Tsc1 inactivation in a mouse model of tuberous sclerosis complex.
Zeng LH; Rensing NR; Zhang B; Gutmann DH; Gambello MJ; Wong M
Hum Mol Genet; 2011 Feb; 20(3):445-54. PubMed ID: 21062901
[TBL] [Abstract][Full Text] [Related]
14. Aberrant beta-catenin signaling in tuberous sclerosis.
Mak BC; Kenerson HL; Aicher LD; Barnes EA; Yeung RS
Am J Pathol; 2005 Jul; 167(1):107-16. PubMed ID: 15972957
[TBL] [Abstract][Full Text] [Related]
15. Evidence for separable functions of tuberous sclerosis gene products in mammalian cell cycle regulation.
Miloloza A; Kubista M; Rosner M; Hengstschläger M
J Neuropathol Exp Neurol; 2002 Feb; 61(2):154-63. PubMed ID: 11853018
[TBL] [Abstract][Full Text] [Related]
16. Structure of the Tuberous Sclerosis Complex 2 (TSC2) N Terminus Provides Insight into Complex Assembly and Tuberous Sclerosis Pathogenesis.
Zech R; Kiontke S; Mueller U; Oeckinghaus A; Kümmel D
J Biol Chem; 2016 Sep; 291(38):20008-20. PubMed ID: 27493206
[TBL] [Abstract][Full Text] [Related]
17. Interaction between hamartin and tuberin, the TSC1 and TSC2 gene products.
van Slegtenhorst M; Nellist M; Nagelkerken B; Cheadle J; Snell R; van den Ouweland A; Reuser A; Sampson J; Halley D; van der Sluijs P
Hum Mol Genet; 1998 Jun; 7(6):1053-7. PubMed ID: 9580671
[TBL] [Abstract][Full Text] [Related]
18. Tuberin phosphorylation regulates its interaction with hamartin. Two proteins involved in tuberous sclerosis.
Aicher LD; Campbell JS; Yeung RS
J Biol Chem; 2001 Jun; 276(24):21017-21. PubMed ID: 11290735
[TBL] [Abstract][Full Text] [Related]
19. Co-localization of TSC1 and TSC2 gene products in tubers of patients with tuberous sclerosis.
Johnson MW; Emelin JK; Park SH; Vinters HV
Brain Pathol; 1999 Jan; 9(1):45-54. PubMed ID: 9989450
[TBL] [Abstract][Full Text] [Related]
20. Renal Transcriptome and Metabolome in Mice with Principal Cell-Specific Ablation of the Tsc1 Gene: Derangements in Pathways Associated with Cell Metabolism, Growth and Acid Secretion.
Zahedi K; Barone S; Brooks M; Murray Stewart T; Casero RA; Soleimani M
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
